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Transmitochondrial cybrids and multiple OMICs ap-
proaches were used to understand mitochondrial
reprogramming and mitochondria-regulated cancer
pathways in triple-negative breast cancer (TNBC).
Analysis of cybrids and established breast cancer
(BC) cell lines showed that metastatic TNBC main-
tains high levels of ATP through fatty acid b oxida-
tion (FAO) and activates Src oncoprotein through
autophosphorylation at Y419. Manipulation of FAO
including the knocking down of carnitine palmitoyl-
transferase-1A (CPT1) and 2 (CPT2), the rate-limiting
proteins of FAO, and analysis of patient-derived
xenograft models confirmed the role of mitochon-
drial FAO in Src activation and metastasis. Analysis
of TCGA and other independent BC clinical data
further reaffirmed the role of mitochondrial FAO and
CPT genes in Src regulation and their significance
in BC metastasis.INTRODUCTION
Althogh the Warburg effect has been validated by numerous
studies, there has also been tremendous advancements toward
the understanding of many aspects of cancer metabolism,
including the roles of glycolysis, glutaminolysis, fatty acid (FA)
synthesis, andmost recently, fatty acid B oxidation (FAO) (Carra-
cedo et al., 2013; Ward and Thompson, 2012). Multiple reports
have suggested that, despite enhanced glycolysis, cancer cells2154 Cell Reports 14, 2154–2165, March 8, 2016 ª2016 The Authorscan produce a significant fraction of their ATP via mitochondrial
respiration (Caino et al., 2015; LeBleu et al., 2014; Lu et al., 2015;
Maiuri and Kroemer, 2015; Tan et al., 2015; Viale et al., 2015;
Ward and Thompson, 2012; Xu et al., 2015). In a growing tumor,
adaptive metabolic reprogramming, precipitated in part by
oncogenic transformation, gives cancer cells the advantage of
active proliferation, functional motility, and metastasis (Basak
and Banerjee, 2015; Caino et al., 2015; LeBleu et al., 2014).
A recent study by Tan et al. has described that, when mtDNA-
depleted tumor cells (r0 cells) were injected into mice, they
enhanced their tumor growth property by acquisition of mtDNA
from the host mouse cells and reassembling a mitochondrial
electron transport chain complex (ETC) and respiratory function
(Tan et al., 2015). These observations suggest that, at least in
selected subgroups of cancers, mitochondrial biogenesis is
important for their oncogenesis and tumor progression.
Based on the differential metabolic preferences of a tumor cell
compared to a normal cell, targeting tumor cell-specific meta-
bolic characteristics is increasingly becoming a more attractive
potential therapeutic strategy (Caino et al., 2015; Ghosh et al.,
2015; Ward and Thompson, 2012). To better evaluate therapeu-
tic potentials, it is important to elucidate how these metabolic
programs couple with or converge into oncogenic signals such
as those leading to unbridled growth, reduced apoptosis, and
metastatic potential. The extensive crosstalk between the mito-
chondria and the nucleus known as ‘‘mitochondrial retrograde
regulation’’ (MRR) is triggered by mitochondrial dysfunction/re-
programming and is not a simple on-off switch but rather re-
sponds in a continuousmanner to the changingmetabolic needs
of the cell (Erol, 2005).
Triple-negative breast cancer (TNBC) are negative for estro-
gen receptor (ER), progesterone receptor (PR), and human
epidermal growth factor receptor 2 (HER-2) amplification. TNBC
suffers a poor prognosis compared to other cancer subtypes,
caused by significant heterogeneity and limited understanding
of the driver signaling pathways. Thus, for TNBC, clinical benefit
from currently available targeted therapies is limited, and new
therapeutic strategies are urgently needed. Most of the conven-
tional chemotherapeutic agents, the current clinical standard for
TNBC treatment, generally kill cells by activating mitochondrial
apoptosis (Costantini et al., 2000; Hail, 2005). Thus, understand-
ing MRR and the mitochondria-mediated oncogenic signature is
critical to improve understanding of the currently limited known
etiology and treatment resistance of TNBC.
Mitochondrial studies using whole-cell approaches make it
difficult to distinguish mitochondria-specific effects from those
contributed by the nucleus. We overcome this gap by using
transmitochondrial cybrid (cybrid) models for mitochondria func-
tion and pathway discovery (Ishikawa et al., 2008; Kaipparettu
et al., 2010, 2013; King and Attardi, 1989; Vithayathil et al.,
2012). The cybrid system is an excellent tool to compare different
mitochondria on a common defined nuclear background to un-
derstand mitochondria-specific effects on cellular properties.
We have used the cybrid approach to discover mitochondria-
regulated energy and cancer pathways in TNBC. These initial
findings were then further validated in established breast cancer
(BC) cell lines, patient-derived xenograft (PDX) models, and BC
patient data.
c-Src is a proto-oncogene involved in signaling that culminates
in the control of multiple biological functions. Like most protein
kinases, Src family members require phosphorylation within a
segment of the kinase domain termed the activation loop for full
catalytic activity. The chief phosphorylation sites of human Src
include an activating autophosphorylation of Y419 in the kinase
domain and an inhibitory phosphorylation of Y530 in the regulato-
ry tail. While phosphorylation of Y530 inactivates Src through the
foldingofSrc into aclosed, inaccessible bundle, the full activation
of the Src signature depends on autophosphorylation at Y419
that allows access of the substrate (Aleshin and Finn, 2010; Ros-
koski, 2015; Zhang and Yu, 2012). Src Y530 phosphorylation re-
sults from the action of other protein-tyrosine kinases including
Csk and Chk. Importantly, the doubly phosphorylated enzyme
is active, indicating that Y419 autophosphorylation overrides
inhibition produced by Y530 phosphorylation (Roskoski, 2015;
Zhang and Yu, 2012). Aberrant Src activation plays prominent
roles in cancer formation and progression (Aleshin and Finn,
2010; Finn, 2008; Mayer and Krop, 2010). The Src pathway is
one of the most commonly upregulated pathways in TNBC (An-
balagan et al., 2012; Tryfonopoulos et al., 2011). Although Src in-
hibitors hold promise in treating metastatic TNBC (Pal and Mor-
timer, 2009; Tryfonopoulos et al., 2011), initial clinical studies
using Src inhibitor monotherapy in unselected patients with
advanced BC showed onlyminor response (Finn et al., 2011; Gu-
calp et al., 2011;Herold et al., 2011;Mayer andKrop, 2010). Since
the discovery of Src approximately 40 years ago,much effort has
been invested in understanding the role of Src in cell regulation
and Src signaling pathways in cancer. Although structural
biology,molecular andcell biology, andgenetic studies havepro-
vided crucial information, the complete picture of molecular
mechanisms and tumor biology of Src signaling remain elusiveCe(Oneyama and Okada, 2015; Roskoski, 2015; Sirvent et al.,
2015; Zhang and Yu, 2012). Therefore, elucidating how aberrant
Src activation occurs in the cancer cells and which mechanisms
fuel this process would be of utmost interest in the cancer field.
Here, we use cybrid technology, BC cell line, PDXmodels, and
BC patient data to understand the role of energy reprogramming
in metastatic TNBC and its significance in the regulation of tumor
properties via the activation of Src cancer pathway. This study
reports the significance of mitochondrial energy reprogramming
in the regulation of a major cancer pathway by posttranslational
modification.
RESULTS
Characteristics of Mitochondrial Origin Determine
Oncogenic Properties of the Cybrids
In order to understand the mitochondria-regulated energy and
cancer pathways in TNBC, we have generated cybrid models
with the moderately metastatic TNBC cell line SUM159 as the
nuclear background and mitochondria from TN benign breast
cells MCF-10A and A1N4, moderately metastatic SUM159,
and highly metastatic MDA-MB-231 (MDA231) TNBC cells (Fig-
ure 1A). mtDNAs from original cell lines used for the generation of
cybrids were sequenced (Table S1). Cybrids were confirmed by
analyzing their nuclear DNA and mtDNA variations. mtDNA copy
numbers were quantified from each cybrid clone and only clones
with comparable copy numbers were used for further analysis.
These cybrids showed in vitro and in vivo tumor-like properties
according to their mitochondrial origin. Mitochondria derived
from benign cells almost completely abolished the in vitro and
in vivo tumor properties of SUM159 cells (Figures 1A–1D) result-
ing in significantly lower number of colonies on soft agar
(Figure 1B), like their mitochondrial donor cells (Figure S1), and
abolished cell migration potential in wound healing assays (Fig-
ure 1C). However, mitochondria from metastatic cells signifi-
cantly induced tumor properties. In vivo tumor formation assay
after mammary gland transplantation suggested that introduc-
tion of benign mitochondria resulted in complete inhibition of
the in vivo tumor formation potential of SUM159 cells (Figures
1D and S1).
Src Autophosphorylation Depending
on Mitochondrial ETC
We performed microarray analysis in the cybrid models to iden-
tify pathways that are altered according to the mitochondrial
regulation. One of the major pathways altered was the Src onco-
genic pathway (Figure 1E). Analysis of multiple BC cell lines sug-
gested that pSrc (Y419) is increased in TNBC cell lines compared
to benign or ER+ BC cell lines (Figure 1F). The Cancer Genome
Atlas (TCGA) data analysis confirmed that Src (Y419) phosphor-
ylation is significantly increased in the basal subtype of BC
compared to hormone positive luminal A and B subtypes of
BC (Figure 1G). Reverse phase protein array (RPPA) data were
analyzed from PDX models with and without distant metastatic
potential. These PDX models are derived directly from BC pa-
tients without intervening culture in vitro and are maintained by
serial transplantation from one animal to another, so that they
have never been exposed to in vitro culture conditions. As all Reports 14, 2154–2165, March 8, 2016 ª2016 The Authors 2155
Figure 1. Mitochondrial Characteristics Re-
gulate Oncogenic Properties
(A) SUM159 TNBC cybrid model with mitochon-
dria from benign (MCF10A and A1N4), moderately
metastatic (SUM159), and highly metastatic
(MDA231) TN cells under a defined nuclear back-
ground of SUM159 mtDNA depleted r0 cells. The
cybrids are named as C-MCF10A, C-A1N4,
C-SUM159, and C-MDA231, respectively. Images
of soft agar colony formation assay of mitochon-
drial donor cells and cybrids are shown with the
cartoon. Colonies are red marked using GelCount
software.
(B) Quantification of soft agar colonies of cybrids.
(C) Analysis of wound healing assays performed in
an IncuCyte ZOOM kinetic imaging system with
live-cell imaging every 3 hr. While cybrids with
mitochondria from cancer cells completely healed
(100% relative wound density) within 24 hr, cybrids
with mitochondria from benign cells could not heal
the wound even after 36 hr.
(D) Bioluminescence imaging of tumor growth
in cybrids. Mice injected in the mammary fat
pads with cybrids C-A1N4 (right [R]; cartooned
with green mitochondria) and C-SUM159 (left
[L]; cartooned with pink mitochondria). Benign
mitochondria (A1N4) abolished the in vivo tumori-
genicity of SUM159 cells. Pellets show the lumi-
nescence property of both cybrids.
(E) Microarray analysis of cybrids suggest that
Src transcriptional signature (Creighton, 2008)
is abolished in C-A1N4 with benign mitochondria.
c-Src upregulated genes are down and c-Src
downregulated genes are up in C-A1N4 compared
to C-SUM159. Yellow shows higher and blue
shows lower expression.
(F) pSrc (Y419) analysis in benign, ER positive, and
TNBC cell lines showing increased Src Y419
phosphorylation in TNBC cells compared to
benign or ER+ cells.
(G) The RPPA data from TCGA BC patient tumors
suggest an increased pSrc (Y419) expression in
basal subtype compared to hormone positive
subtypes. The asterisk represents significant in-
crease in the relative pSrc (Y419) expression
in basal subtype compared to luminal A and B
subtypes.
(H) Comparison of RPPA data from TNBC PDX
models with distant metastatic (DM) and non-
distant metastatic (No DM) potential, suggesting
pSrc (Y419) level is significantly upregulated in
PDXs with DM potential.
See also Figure S1.
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Figure 2. Src Autophosphorylation Is Regu-
lated by Mitochondrial Properties
(A) Western blot showing decreased Src (Y419)
phosphorylation in cybrids with mitochondria from
benign cells compared to TNBC mitochondria.
However, there was no major difference in the total
Src levels or Src (Y530) phosphorylation status.
Complex IV subunit II and b-actin were used as
mitochondrial and nuclear loading controls.
(B) Depletion of mitochondria (r0 cells) abolished
pSrc (Y419) in parental cells but reappeared in
cybrids with TNBC mitochondria with no major ef-
fect on total Src, pSrc (Y530), and CSK.
(C) Cell fractional analysis suggests localization of
pSrc in mitochondrial fraction (M, mitochondria; C,
cytoplasmic; N, nuclear fraction).
(D) pSrc (Y419) and its target pFAK in cybrids are
abolished after treatment with a selective inhibitor
for Src-family kinases, PP2.
(E and F) TNBC cells treated with glycolysis in-
hibitors 3-BP (E) and DCA (F), showing no consid-
erable decrease in Src phosphorylation status.
(G) Treatment with glutamine pathway inhibitor
AOA did not show major reduction in Src (Y419).
(H and I) Treatment with ROS scavenger NAC in
cybrids (H) and parental cell SUM159 (I) did not
abolished the increased Src (Y419) phosphoryla-
tion in TNBC.
See also Figures S2 and S3.result, these xenografts maintain histological and molecular fea-
tures of the tumor of origin, including their characteristic expres-
sion levels (Zhang et al., 2013). Multiple PDX lines were included
from some of the patients (Figures S1C and S1D). Analysis sug-
gested significantly increased pSrc (Y419) levels in TNBC PDXs
with distant metastasis (Figures 1H and S1C), while no signifi-
cant difference was observed with pSrc (Y530) (Figures S1D
and S1E).
Extensive evaluation of cybrid models and parental cells
confirmed that Src (Y419) is activated by metastatic TNBCmito-
chondria without any major effect at Y530 (Figures 2A and 2B).
Cellular fractionation (Figure 2C) confirmed the localization of
Src and pSrc (Y419) in TNBC mitochondria. Src (Y419) auto-
phosphorylation (Figures 2D and S2A) of cybrids and cancer po-
tential (Figure S2) of cybrids, and parental cells were decreased
by treatment with the Src inhibitors PP2 and dasatinib, suggest-
ing that their tumorigenic properties depend on the Src pathway.Cell Reports 14, 2154–216Inhibition of glycolysis by 3-bromopyru-
vate (3-BP) or dichloroacetate (DCA) did
not decrease the increased pSrc (Y419)
in TNBC cells (Figures 2E and 2F). Inhibit-
ing the glutamine pathway using amino-
oxyacetic acid (AOA) (Figure 2G) or scav-
enging basal reactive oxygen species
(ROS) using N-acetylcysteine (NAC) (Fig-
ures 2H and 2I) also did not inhibit the
induced Src (Y419) autophosphorylation
in TNBC cell lines or cybrids. We then
analyzed the role of mitochondrial ETC
complexes that are responsible for ATPgeneration inside mitochondria in the regulation of Src auto-
phosphorylation. Interestingly treatment with agents that target
ETC including the complex 1 inhibitor rotenone (Figures 3A
and 3B), the complex III inhibitor antimycin-A (Figures 3C and
3D), and the ATP synthase inhibitor oligomycin (Figures 3E and
3F) dose-dependently reduced Src (Y419) autophosphorylation
both in parental TNBC cells and in cybrids. However, ETC inhibi-
tion did not show any major effect on the phosphorylation of Src
(Y530) (Figures 3B, 3D, and 3F). In vitro phosphorylation experi-
ments suggested that Src (Y419) autophosphorylation but not
pSrc (Y530) is directly dependent on the ATP concentration (Fig-
ures 3G and 3H). Though other known mitochondria-localizing
Src family kinases (SFKs) (Acı´n-Pe´rez et al., 2014; Salvi et al.,
2002; Vahedi et al., 2015) are also present in the TNBC cells
we used (Figure S3A), as observed with pSrc (Y530) their phos-
phorylation status did not show major alterations according to
the mitochondrial character of the cybrid (Figures S3B and S3C).5, March 8, 2016 ª2016 The Authors 2157
Figure 3. Src (Y419) Phosphorylation De-
pends on ATP from ETC
(A–F) Cells were treated with the mitochondrial
ETC complex I inhibitor Rotenone (A and B), the
complex III inhibitor Antimycin-A (C and D), or the
complex V inhibitor Oligomycin (E and F). Inhibitors
dose-dependently inhibit Src (Y419) autophos-
phorylation in parental cells (A, C, and E) and cy-
brids (B, D, and F), respectively, suggesting a
critical role of ATP from mitochondrial ETC in Src
Y419 autophosphorylation.
(G) Western blot of in vitro phosphorylation assay
of purified Src protein using varying concentra-
tions of ATP. Src (Y419) autophosphorylation is
increased with the ATP concentration. However,
no ATP dose dependency is observed in pSrc
(Y530).
(H) Quantification of the average pSrc/Src ratio
from three independent in vitro phosphorylation
experiments.
Error bars, SEM.Metastatic TNBC Cells Demonstrate Energy
Dependency on Mitochondrial FAO
Proteomic analysis suggested that several proteins related to
mitochondrial FAO are upregulated in cybrids with mitochondria
derived frommetastatic TNBC (Figures 4A, S4A, and S4B). Mass
spectrometry analysis of carnitines in parental cells showed
increased levels of several carnitines in metastatic TNBC cells
(Figure 4B). Oxygen consumption rate (OCR) analysis suggested
a sharp decrease in OCR after treatment with etomoxir (ETX),
which suppresses mitochondrial FAO rate-limiting enzyme,
carnitine palmitoyltransferase-1A (CPT1) (Figures 4C and S4C).
While ETX treatment decreased the OCR, it also simultaneously
increased the glycolysis, as seen by the high extracellular acidifi-
cation rate (ECAR) (Figures S4D and S4E). Medium containing
palmitate conjugated with BSA significantly increased OCR and
basal respiration of TNBC cells and cybrids with mitochondria
from TNBC compared to benign cells and cybrids containing
mitochondria from benign cells, respectively (Figure 4D). Neutral
lipid staining suggested increased lipid formation after ETX treat-
ment in TNBCmetastatic cells and cybrids with TNBCmitochon-
dria but not in ER+ BC cells (Figures 4E and S4F). A CO2 trap2158 Cell Reports 14, 2154–2165, March 8, 2016 ª2016 The Authorsassay using 14C radiolabeled FA oleate-
BSA further confirmed increased FAO in
metastatic TNBC cells and cybrids (Fig-
ure 4F). Moreover, CPT1 activity is upre-
gulated in metastatic TNBC cells and cy-
bridswithTNBCmitochondria (Figure 4G).
Mitochondrial FAO Inhibitors or
Knockdown of CPT1 and 2 Genes
Abolish Src Autophosphorylation
Inhibition of FAO by ETX (Figures 5A–5C)
or perhexiline (PHX) (Figure 5D) dose-
dependently abolished Src activation in
parental cells and cybrids. In reverse ex-
periments, we activated FAO by treat-
ment with FA conjugated with BSA (Fig-ure 5E) or L-carnitine (Figure 5F) as substrates of CPT1 to
understand the induction of pSrc (Y419) in cybrids with benign
mitochondria. As expected, activation of FAO by FA and L-carni-
tine induced pSrc (Y419) in cybrids with benign mitochondria
(Figures 5E and 5F). ROS induction is known to decrease
CPT1 functional activity (Setoyama et al., 2013). Antimycin-A,
which inhibits Src autophosphorylation (Figures 3C and 3D),
also significantly induces mitochondrial ROS (Figures S5A). To
further understand the role of ROS in Src (Y419) autophosphor-
ylation, cells were treated with H2O2, antimycin-A, and/or ROS
scavenger NAC (Figure S5). As expected, treatment with H2O2
and antimycin-A inhibited pSrc (Y419) in the parental cell line
(Figure 5G) and the cybrid (Figure S5C). The H2O2-mediated in-
hibition was reversed by the addition of NAC in H2O2-treated
cells but not in antimycin-A-treated cells (Figure 5G). This sug-
gests that the ETC activity is important in the activation of pSrc
(Y419). Another important question is, what happens to Src
(Y419) autophosphorylation in conditions where tumor cells
are under hypoxia, where ETC function is diminished? Parental
cells were analyzed under normoxic and hypoxic conditions.
As expected, Src (Y419) phosphorylation was abolished under
Figure 4. Metastatic TNBC Shows Energy
Dependence on Mitochondrial FAO
(A) Shotgun Jet Stream Proteomics analysis of cy-
brids on a UHPLC/AJS-iFunnel Q-TOF suggested
increased (yellow) expression of mitochondrial FAO
proteins in cybrids with cancer mitochondria.
(B) Mass spectrometric analysis of carnitines in
benign and metastatic TNBC cells showing
increased carnitine levels in TNBC cells (MDA231
and SUM159) compared to benign cells (A1N4).
(C) Seahorse XF analysis suggesting that addition
of FAO inhibitor almost completely inhibited the
increased respiration of lung metastatic TNBC
cells (MDA231-LM).
(D) Seahorse XF analysis using medium contain-
ing palmitate-BSA. Metastatic cells and cybrids
with mitochondria from metastatic cells showed
increased basal respiration compared to benign
cells and cybrids with mitochondria from benign
cells, respectively.
(E) Flow cytometry analysis using the allophyco-
cyanin (APC) channel after lipidTOX neutral lipid
staining. Treatment with the ETX enhanced the
APC florescence in a TNBC cell line (MDA231) and
C-MDA231 cybrids.
(F) CO2 trap assays using
14C-labeled oleate in
parental cells (left) and cybrids (right) confirm
significantly higher FAO in metastatic TNBC cells
and its cybrids compared to benign cells and its
cybrids.
(G) CPT1 activity assay in whole-cell lysate from
TNBCcellMDA231-LMandER+ cellMCF7 showing
increased CPT1 activity in metastatic TNBC cells
(left). Isolated mitochondria from cybrids with mito-
chondria from cancer cells (C-SUM159) and from
benign cells (C-A1N4) show increasedCPT1 activity
in C-SUM159 cybrid (right).
See also Figure S4.hypoxia, confirming its dependence on ATP generation from
mitochondrial oxidative phosphorylation (Figure 5H).
Gene expression data from MDA231 cells confirm that inhibi-
tion of FAO by ETX or CPT small hairpin RNA (shRNA) reverse
the published Src-regulated gene pattern (Creighton, 2008) (Fig-Cell Reports 14, 2154–216ure 6A). The known Src upregulated genes
are downregulated and Src down-
regulated genes are upregulated in FAO-
inhibited cells. Knockdown of CPT1
(Figure 6B) or CPT2 (Figure 6C) also in-
hibited Src (Y419) autophosphorylation
as observed with ETX (Figure 5). However,
FAO inhibitiondid not showmajor variation
in the expression of Src-related proteins
(Figure S6A) or phosphorylation of other
analyzed SFKs (Figures S6A–S6D).
FAO Inhibition Abolishes Tumor and
Metastatic Properties
In vitro analysis of tumor properties
showed the critical role of FAO in TNBC
cancer progression (Figures 6D–6I). Col-ony formation assays of TNBC cell lines using agar medium
with ETX suggested dose-dependent decrease of colony forma-
tion (Figure 6D). Pretreatment of cells with ETX also significantly
decreased the colony formation potential of TNBC cell lines (Fig-
ure 6E). Similarly, ETX treatment significantly decreased the5, March 8, 2016 ª2016 The Authors 2159
Figure 5. Inhibition of FAO Abolishes Src
(Y419) Phosphorylation
(A) Treatment with ETX dose-dependently
decreased Src (Y419) autophosphorylation in
MDA231-LM cells (left) and SUM159 cells (right).
(B) Time dependency for ETX-mediated Src
dephosphorylation in MDA231 cells.
(C) Treatment with ETX depletes pSrc (Y419)
phosphorylation in cybrids with mitochondria
from cancer cells but not in cybrids with benign
mitochondria.
(D) Treatment with another CPT1 inhibitor PHX
also dose-dependently depleted pSrc (Y419) in
MDA231 (left) and SUM159 (right) cells.
(E) Stimulation of FAO by treatment with BSA-
conjugated FA increased pSrc (Y419) levels in
cybrids with benign mitochondria.
(F) Addition of known FAO enhancer L-carnitine
also increased pSrc (Y419) in cybrids with benign
mitochondria.
(G) Stimulation of ROS with H2O2 and antimycin-A
inhibits pSrc (Y419) in SUM159 cells. Addition of
NAC reverses H2O2-mediated but not antimycin-
A-mediated inhibition of pSrc (Y419).
(H) pSrc (Y419) phosphorylation is depleted in
parental cells (upper panel) and cybrids (lower
panel) cultured under hypoxic condition with
1% O2.
See also Figure S5.migration potential of cybrids and parental cells (Figures 6F and
6G). Knockdown of CPT1 or CPT2 by shRNA also significantly in-
hibited the transwell migration potential of MDA231 cells (Fig-
ure 6G). ETX treatment (Figure 6H) or knockdown of CPT genes
(Figure 6I) also significantly inhibited the wound healing poten-
tial. However, ETX-mediated inhibition was significantly lower
in CPT knockdown cells compared to control cells (Figure S6E).
RPPA and gene expression data from TCGA patient tumor
analysis suggested a significant positive correlation between
CPT1AmRNA expression and Src (Y419) phosphorylation status
in basal BC subtypes (Figure 7A). However, no such correlation
was observed in other BC subgroups (Figure S7A). In addition,
no significant correlation was observed with Src (Y530) phos-
phorylation status (Figure S7B). CPT1 and CPT2 shRNA also
significantly decreased the tumor growth of MDA231 cells com-
pared to scrambled shRNA transfected control cells (Figure 7B).
Cell line data validated using PDX models (Zhang et al., 2013).
One week after PDX transplantation to the mammary gland,2160 Cell Reports 14, 2154–2165, March 8, 2016 ª2016 The Authorsthe mice were treated with ETX for
2weeks. Short-term ETX treatment signif-
icantly delayed the palpable tumor
appearance (Figure 7C) and tumor growth
of the PDX (BCM-2147, Figure S7C). In
mice transplanted with another PDX
model (BCM-4013), ETX was adminis-
tered after the tumor size reached around
150 mm3. As observed above, ETX treat-
ment significantly decreased the tumor
growth (Figure 7D). For distant metastasis
analysis, MDA231 cells were pretreatedfor 2 days with ETX before tail vein injection. The ETX treatment
continued for onemore week in mice. After 3 weeks, biolumines-
cence imaging showed considerably lower metastatic signals in
ETX-treated mice (Figure 7E). Also, a significantly low number of
metastatic nodules was observed in ETX-treated mice, confirm-
ing the role of FAO in distant metastatic potential (Figures 7F and
7G). Similar results were observed even without ETX pre-treat-
ment (Figures S7D and S7E). Finally, an independent unselected
BC patient dataset (n = 1,302) with long-term clinical follow-up
data suggested that high CPT1A mRNA expression in the tumor
promotes distant metastasis (Kessler et al., 2012) (Figure 7H).
DISCUSSION
Cancer cells essentially undergo ametabolic rewiring program to
meet the demands of a cancer phenotype (Cantor and Sabatini,
2012). This concept of metabolic reshuffling emanates from
Warburg’s hypothesis stating that cancer cell mitochondria are
Figure 6. Mitochondrial FAO Inhibition Re-
presses In Vitro Tumor Properties
(A) Src gene signature from microarray analysis in
MDA231 cells. Inhibition of FAO by ETX or CPT
shRNA broadly reversed the Src-regulated gene
signature compared to scrambled shRNA-trans-
fected cells.
(B and C) Knockdown of CPT1 (B) and CPT2
(C) by shRNA downregulated Src (Y419) phos-
phorylation.
(D) ETX inhibited colony formation in MDA231-LM
cells.
(E) Two days pretreatment with ETX significantly
reduced the soft agar colony formation potential of
MDA231 and SUM159 cells. ETX was not added in
the soft agar medium.
(F andG) Transwell migration assay. ETX treatment
significantly decreased the migration potential of
cybrids (F) and parental cells (G).
(H and I) Images of wound healing assay in
SUM159 cells (36 hr) and MDA231 cells (15 hr).
Mean percentage of wound confluence analyzed
from live-cell imaging every 3 hr shows signifi-
cantly reduced wound healing potential after ETX
treatment (H) or knockdown of CPT genes by
shRNA (I).
See also Figure S6.defective and hence switch to energy inefficient pathways
(glycolysis). Our data suggest that mitochondrial energy reprog-
ramming to FAO is critical in the activation of Src signaling in
TNBC. Several recent reports questioned the conventional
concept that in cancer cells the energy is produced only through
glycolysis without major contribution frommitochondrial respira-
tion (Biswas et al., 2012; Caino et al., 2015; Carracedo et al.,
2013; LeBleu et al., 2014; Liu et al., 2015; Maiuri and Kroemer,Cell Reports 14, 2154–2162015; Tan et al., 2015; Villanueva, 2015;
Ward and Thompson, 2012; Xu et al.,
2015). However, the vast majority of the
research into cancer metabolism has
been limited to a handful of metabolic
pathways, while other pathways have re-
mained in the dark (Carracedo et al.,
2013). In the past decade, researchers
have revisited the Warburg theory and
reached a better understanding of the
‘‘metabolic switch’’ in cancer cells,
including the intimate and causal relation-
ship between cancer genes and meta-
bolic alterations, and their potential to be
targeted for cancer treatment (Biswas
et al., 2012; Carracedo et al., 2013;
Ward and Thompson, 2012). Recently,
alternative energy pathways like FAO
have been getting increasing attention in
cancer research (Balaban et al., 2015;
Harjes et al., 2016). Association of FAO
with apoptotic machinery has been re-
ported in cancer (Balaban et al., 2015;
Samudio et al., 2010), suggesting thatFA metabolism provides a survival advantage to the cancer
cells and closely communicates with the cancer signaling
pathways.
The alterations in malignant mitochondria or the metabolic
pathways governing mitochondrial function vary by cancer
type and level of disease progression (Constance and Lim,
2012). Drugs that target mitochondria and exert anti-cancer ac-
tivity have become a focus of recent research due to their great5, March 8, 2016 ª2016 The Authors 2161
Figure 7. Mitochondrial FAO Regulates
In Vivo Tumor Properties
(A) RPPA and gene expression data from the TCGA
patient database (n = 105) show significant positive
correlation between Src (Y419) status and relative
CPT1 mRNA expression (r = 0.34, p < 0.0005,
Pearson’s correlation).
(B) Bioluminescence images of mice showing that
knockdown of CPT1 or CPT2 in MDA231 cells in-
hibits in vivo tumor growth potential.
(C and D) ETX treatment in PDX. PDX BCM-2147
and BCM-4013 were transplanted to the fourth
mammary glands of mice. BCM-2147-trans-
planted mice were treated 1 week after the trans-
plantation. BCM-4013-transplanted mice were
treated after the tumors reached around 150 mm3
(treatment period illustrated with the yellow lines).
ETX treatment significantly delayed the palpable
tumor formation of BCM-2147 (C) and decreased
the tumor growth of BCM-4013 (D) (*p < 0.05 in
one-tailed t test).
(E–G) Significance of FAO in distant metastasis.
Control and ETX-pretreated (2 days) MDA231 cells
(1.5 3 105) were injected in the tail vein of NOD
SCID Gamma mice. ETX treatment was continued
in the mice for one more week. Bioluminescence
imaging after 3 weeks showed decreased metas-
tasis in ETX-treatedmice (E). Lung and liver images
(nodules indicated with white arrows) (F) and
nodule count (G) confirm significantly decreased
metastasis in ETX-treated mice compared to
control-treated mice.
(H) Gene expression data from independent BC
datasets (n = 1,302) show significantly increased
risk of distant metastasis with high CPT1 mRNA
expression. p value by log-rank statistic.
See also Figure S7.clinical potential (Neuzil et al., 2013). Thus, mitochondrial energy
reprogramming from regulated oxidative phosphorylation and
glycolysis to alternative pathways like mitochondrial FAO will
have a major influence on tumor response to currently available
anticancer drugs. Sensitizing mitochondria (Ni Chonghaile et al.,
2011) may be an ideal way to overcome currently non-targetable
tumors like TNBC. Mitochondria are known to harbor variations
in mtDNA that have been linked to BC development (Ishikawa2162 Cell Reports 14, 2154–2165, March 8, 2016 ª2016 The Authorset al., 2008; Ohsawa et al., 2012). How-
ever, here mtDNA sequencing did not
show any common variation that could
contribute to the energy reprogramming
in the analyzed cell models. Thus, the
study focused on overall functional char-
acteristics of the mitochondria rather
than individual mtDNA variations.
Src is one of the most commonly upre-
gulated pathways in TNBC (Tryfonopou-
los et al., 2011). However, even with
promising preclinical studies on the sig-
nificance of the Src pathway in TNBC, sin-
gle-agent like dasatinib studies in patients
with metastatic TNBC did not show a ma-jor clinical advantage in unselected populations (Finn et al., 2011;
Mayer and Krop, 2010; Tryfonopoulos et al., 2011). From the cur-
rent results, it should be noted that these patients with advanced
tumors might have larger tumors in which several tumor areas
are hypoxic and cannot depend on mitochondrial respiration
for their survival. Our data show that those tumors without active
mitochondrial oxidative phosphorylation, as in a hypoxic situa-
tion, may not maintain Src activity via its autophosphorylation
(Figure 5H). Thus, those tumors or tumor areas may be depend-
ing on alternative cancer pathways and require combination
therapies with other mitochondrial targets or chemotherapeutic
agents. Identifying which patients should be selected for Src-
directed therapies will be important to the clinical success of
these agents.
Mitochondrial protein phosphorylation is an important mech-
anism for the modulation of mitochondrial function (Acı´n-Perez
et al., 2009; O’Rourke et al., 2011). Previous reports including
immunoelectron microscopy studies have shown that Src is
located inside mitochondria, and Src activity is also important
for the regulation of mitochondrial functions and cell viability
(Hebert-Chatelain, 2013; Miyazaki et al., 2003; Salvi et al.,
2002; Tibaldi et al., 2008). Src can phosphorylate several
proteins involved in the mitochondrial ETC. Cells with high
Src activity are also known to maintain high ETC activity, as
several mitochondrial proteins were shown to be substrates
of Src kinases (Hebert-Chatelain, 2013). For example, Y193
at NADH dehydrogenase (ubiquinone) flavoprotein 2 of res-
piratory complex I, which is indispensable for NADH dehydro-
genase (complex I) activity and ATP production, Y215 at
succinate dehydrogenase A of complex II, as well as direct
phosphorylation of cytochrome c oxidase subunit II of complex
IV are some of the mitochondrial phosphorylation targets for
Src (Miyazaki et al., 2003; Ogura et al., 2012). Together with
these findings, our data propose that increased FAO in TNBC
cells activates Src autophosphorylation, and activated Src
phosphorylates mitochondrial ETC proteins to maintain its acti-
vated status.
Studies have also shown that Src regulates ROS production
in localized subcellular districts including mitochondria. Mito-
chondrial Src can phosphorylate flotillin-1 at Y56 and Y149,
which are critical for its interaction with complex II and the pre-
vention of ROS production (Ogura et al., 2014). Increased ROS
can inhibit CPT1 enzymatic activity (Setoyama et al., 2013).
Moreover, L-carnitine is considered as a potential anti-oxidant
(Mescka et al., 2011; Ribas et al., 2014) and L-carnitine can
protect the H2O2-induced cytotoxity by enhancing CPT1 activ-
ity (Li et al., 2012). All these confirm the role of ROS in the
downregulation of FAO via inhibition of CPT1. Our results
also support these findings in TNBC. Treatment with H2O2 or
antimycin-A (which increases mitochondrial ROS) abolishes
Src autophosphorylation (Figure 5G). Interestingly, while ROS
scavengers rescued the H2O2-mediated pSrc (Y419) inhibition,
it could not reverse antimycin-A-mediated pSrc (Y419) inhibi-
tion. However, in addition to increasing ROS, antimycin-A is a
strong inhibitor of complex III function and ETC activity. This
further confirms the importance of ETC activity in the autophos-
phorylation of Src.
Large prospective studies have shown that dietary fat intake is
associated with the risk of postmenopausal invasive BC. The
Women’s Intervention Nutrition Study (WINS) trial reported that
low-fat diet and corresponding weight loss has a favorable effect
on BC recurrence, especially in postmenopausal women with
ER-negative cancer (Hoy et al., 2009). The recent WINS report
highlighted that deaths of women with TNBC were reduced by
up to 54% when they followed a program to reduce their dietary
fat intake (Chlebowski and Blackburn, 2015). This highlights theCesignificance of fat in TNBC progression. Considering our impor-
tant finding on the role of fat metabolism in the activation of the
Src signature in TNBC, it is also possible that, due to a high-fat
environment, mitochondria will reprogram to a FA-dependent
energy pathway in obese TNBC patients. Obese women also
have a greater risk for TNBC than non-obese women, where
menopause status may be a mitigating factor (Pierobon and
Frankenfeld, 2013). In pre-menopausal women, a significant as-
sociation between obesity and TNBC was observed in both
case-case and case-control studies. Clinical data reported
significantly shorter overall survival and disease-free survival in
obese patients with TNBC (Turkoz et al., 2013). Meta analysis
on obesity and TNBC reported that, compared to overweight
and normal-weight individuals, pre-menopausal women with
BMI equal to or greater than 30 have up to a 42% increased
risk of developing TNBC (Pierobon and Frankenfeld, 2013).
Post-menopausal women often present with less aggressive
phenotypes and with estrogen-dependent lesions most likely
driven by the production of steroidal hormones from the adipo-
cytes (Lorincz and Sukumar, 2006; Roberts et al., 2010). Since
TNBC lacks expression of hormone receptors, distinct molecular
mechanisms must link obesity to the TNBC subtype compared
to ER+ tumors. Given the worldwide epidemic of overweight
and obesity, as well as the aggressiveness associated with
TNBC, it is critical to understand the impact of obesity and fat
metabolism in FAO-regulated Src-driven TNBC. This will help
in identifying and targeting a higher risk group of patients with
this aggressive form of BC.
Altogether, these show the role of mitochondrial energy re-
programming to FAO in TNBC and its significance in regulating
the driving protein of a major cancer pathway via its post-
translational modification. Further studies are in progress to
understand the role of obesity in the activation of Src in
TNBC, and to seek suitable combination therapies with mito-
chondrial targets to manage the currently non-targetable
TNBC.EXPERIMENTAL PROCEDURES
Cells, Cybrids, and PDX
Cybrids were generated according to the previously published protocol (Vi-
thayathil et al., 2012). Parental cells and cybrids were used and maintained
in culture as described in the Supplemental Information. TNBC PDX models
(Zhang et al., 2013) were serially transplanted in SCID/Beige female mice (Har-
lan Laboratories). All animal studies were conducted in accordance with the
standard procedures approved by the Baylor College of Medicine Institutional
Animal Care and Use Committee.
In Vivo Tumor Studies
For mammary transplantation assay, 2 3 105 cells and cybrids with Firefly
luciferase or small tumor pieces from PDXs were transplanted into the fourth
mammary fat pads of 4- to 5-week-old SCID/Beige female mice (Zhang
et al., 2013). For tail vein injection, 1.5 3 105 MDA231 cells were injected
into the tail veins of 4- to 5-week-old NOD SCID Gamma mice. Details are
described in the Supplemental Information.
Src Gene Signature Analysis
The mRNA expression profile was performed using U133plus 2.0 array,
and the Src transcriptional signature was analyzed as previously described
(Creighton, 2008). Details are described in the Supplemental Information.ll Reports 14, 2154–2165, March 8, 2016 ª2016 The Authors 2163
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